/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced the promotion of Curran Simpson from Chief Technology and Operations Officer to Chief Operating.
/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed dosing in the expanded Cohort 2 of the Phase I/II trial of RGX-111 for the.
Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products.
Residents throughout the region, including the Metro East, will have access to the resources that come with the federal Build Back Better Challenge Grant.